Navigation Links
BioMarin to Present at the Barclays Capital Global Healthcare Conference
Date:3/17/2010

NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in Miami on Wednesday, March 24, 2010 at 9:30 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products includ
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
2. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
3. BioMarin to Present at the Morgan Stanley Healthcare Conference
4. BioMarin to Present at the Baird Healthcare Conference
5. BioMarin to Present at the Jefferies Healthcare Conference
6. BioMarin to Present at the Goldman Sachs Healthcare Conference
7. BioMarin to Present at the Deutsche Bank Health Care Conference
8. BioMarin to Present at the Baird Growth Stock Conference
9. BioMarin Announces First Quarter 2009 Financial Results
10. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Milwaukee, Wisc. (PRWEB) May 21, 2013 ... equipment parts distributor , will be exhibiting for ... the Advancement of Medical Instrumentation (AAMI) 2013 Conference ... manage, purchase, support, distribute, and manufacture healthcare technologies. ... 1-3 in Long Beach, California. , The ...
(Date:5/21/2013)... 2013 Clinverse, Inc. , ... clinical trials, announced today it has formed a ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship ... and reporting transfer of value at investigator meetings ...
(Date:5/21/2013)... 2013 As the R&D sector ... within the industry to deliver better products, faster. ... pharma companies often means turning big ideas into ... in collaboration with Sensidose AB and Recipharm, is ... products to market sooner. The partnership resulted in ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... 19 MAKO Surgical,Corp. today announced that it has filed ... Exchange Commission relating to a proposed,initial public offering of its ... sold by MAKO Surgical Corp. The,number of shares to be ... been determined. The Company intends to apply to have its ...
... AMSTERDAM, September 19 - IDF Launches ... IDF today issued the new global guideline ... glucose.(1) The guideline emphasizes,that people with diabetes should ... in order to optimize diabetes control and reduce ...
... BASEL, Switzerland, September 19 ,Arpida Ltd (SWX: ARPN) ... summary session of new antimicrobial agents at the ... (ICAAC) in,Chicago. ICAAC is a major scientific conference ... the world gather to discuss the,latest developments in ...
Cached Biology Technology:MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 3Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:5/21/2013)... American Chemical Society (ACS), the world,s largest scientific ... National Meeting & Exposition, September 8-12, 2013, in ... Indiana Convention Center and at area hotels. , ... that span science,s horizons from astronomy to ... and online journalists a rich assortment of spot ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... can lead to big rewards, such as maintaining a healthy ... PhD, describes in a recent report. The article, to be ... of Clinical Nutrition , is written by Hill on behalf ... Food Technologists, and the International Food Information Council. ...
... treatment of many common diseases such as diabetes and ... approach called systems biology, according to leading scientists from ... by the European Science Foundation, the scientists provide a ... medical research over the coming years. Systems biology ...
... in the Climate Change category has found its way, in ... more than three decades ago predicted the existence of climate ... article "Climate Change: Are We on the Brink of a ... the first ever mention of the term "global warming" in ...
Cached Biology News:Key to future medical breakthroughs is systems biology, say leading European scientists 2Key to future medical breakthroughs is systems biology, say leading European scientists 3Wallace S. Broecker wins the BBVA Foundation Frontiers of Knowledge Award in Climate Change 2
...
... CryoMed Freezers for IVF are designed for ... control, ease of setup and operation, and ... status are continuously displayed on the control ... data are printed by way of the ...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
... Source: Crotalus adamanteus venom ... is widely used in studying ... (1) . It hydrolyzes 5'-mononucleotides ... (2) . Phosphodiesterase I cleaves ...
Biology Products: